162 related articles for article (PubMed ID: 12973822)
1. Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
Elg M; Börjesson I; Carlsson S
Biopharm Drug Dispos; 2003 Sep; 24(6):251-7. PubMed ID: 12973822
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
3. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG
J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Eriksson BI; Carlsson S; Halvarsson M; Risberg B; Mattsson C
Thromb Haemost; 1997 Nov; 78(5):1404-7. PubMed ID: 9408027
[TBL] [Abstract][Full Text] [Related]
5. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Furugohri T; Shiozaki Y; Muramatsu S; Honda Y; Matsumoto C; Isobe K; Sugiyama N
Eur J Pharmacol; 2005 May; 514(1):35-42. PubMed ID: 15878322
[TBL] [Abstract][Full Text] [Related]
6. Thrombin inhibition with melagatran does not attenuate renal ischaemia-reperfusion injury in rats.
Nitescu N; Grimberg E; Ricksten SE; Marcussen N; Guron G
Nephrol Dial Transplant; 2007 Aug; 22(8):2149-55. PubMed ID: 17405786
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.
Eriksson BI; Ogren M; Eriksson UG; Kälebo P; Ahnfelt L; Björkström S; Sjöstedt A; Folestad A; Arfwidsson AC; Elvander CS; Frison L
Thromb Res; 2002 Mar; 105(5):371-8. PubMed ID: 12062537
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI
Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328
[TBL] [Abstract][Full Text] [Related]
10. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D
Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Eriksson H; Eriksson UG; Frison L; Hansson PO; Held P; Holmström M; Hägg A; Jonsson T; Lapidus L; Leijd B; Stockelberg D; Säfwenberg U; Taghavi A; Thorsén M
Thromb Haemost; 1999 Mar; 81(3):358-63. PubMed ID: 10102460
[TBL] [Abstract][Full Text] [Related]
12. The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
Carlsson S; Elg M
Blood Coagul Fibrinolysis; 2005 Jun; 16(4):245-9. PubMed ID: 15870543
[TBL] [Abstract][Full Text] [Related]
13. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
[TBL] [Abstract][Full Text] [Related]
14. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
Elg M; Gustafsson D
Thromb Res; 2006; 117(4):429-37. PubMed ID: 15869787
[TBL] [Abstract][Full Text] [Related]
15. The direct thrombin inhibitor melagatran counteracts endotoxin-induced endothelial leukocyte adherence and microvascular leakage in the rat mesentery. Rationale for the treatment of inflammatory disorders beyond sepsis?
Leithäuser B; Fassbender M; Eickhoff M; Elg M; Eichner G; Matthias FR
Clin Hemorheol Microcirc; 2007; 36(4):277-89. PubMed ID: 17502698
[TBL] [Abstract][Full Text] [Related]
16. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
17. Direct thrombin inhibitor prevents delayed graft function in a porcine model of renal transplantation.
Giraud S; Thuillier R; Belliard A; Hebrard W; Nadeau C; Milin S; Goujon JM; Manguy E; Mauco G; Hauet T; Macchi L
Transplantation; 2009 Jun; 87(11):1636-44. PubMed ID: 19502954
[TBL] [Abstract][Full Text] [Related]
18. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Carlsson S; Elg M; Mattsson C
Thromb Res; 2002 Aug; 107(3-4):163-8. PubMed ID: 12431484
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
20. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
